BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
BridgeBio reported Q3 2026 total revenues of $353.2 million, up from $120.7 million a year ago, led by $253.2 million of U.S. Attruby net product revenue that grew about $145 million year over year. Loss from operations narrowed to $11.6 million from $145.2 million, helped by a one-time $75.0 million Bayer BEYONTTRA sales milestone, and cash and marketable securities rose to $1.5 billion, which the company says fully funds all three planned launches.
Key figures
- Revenue
- $353.2 million
- Revenue Yoy
- revenue up $232.5 million vs. $120.7 million prior year (approx. +193%)
- Pdufa dates
- ["BBP-418: November 27, 2026","infigratinib: February 4, 2027","encaleret: May 8, 2027"]
- Nine month revenue
- $791.4 million
- Loss from operations
- $11.6 million
- Bayer sales milestone
- $75.0 million
- Attruby sequential growth
- $31 million
- Attruby net product revenue
- $253.2 million
- Cash and marketable securities
- $1.5 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.